Oncolytics Biotech Inc. ONCY
Health Care · Pharmaceuticals, Biotechnology & Life Sciences · NASDAQ · Canada · oncolyticsbiotech.com
Oncolytics Biotech Inc. is a Calgary-based biopharmaceutical company developing pelareorep, an intravenously delivered immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies. Pelareorep induces selective tumor lysis and promotes an inflamed tumor phenotype through innate and adaptive immune responses, turning cold tumors hot to enhance anti-cancer immunity. The company's lead programs include registration-enabling studies in metastatic breast cancer and pancreatic cancer, with the drug also trading on NASDAQ under the symbol ONCY.
Key ratios
ReturnOnAssets TTM -1.61
ReturnOnAssets 2025 -1.61
ReturnOnAssets 2024 -0.74
ReturnOnAssets 2023 -0.55
ReturnOnEquity TTM -101.88
ReturnOnEquity 2025 -101.88
ReturnOnEquity 2024 -1.89
ReturnOnEquity 2023 -1.03
Recent news
Oncolytics Biotech® Receives Fast Track Designation for Pelareorep in Second-Line and Later Anal Cancer
2026-07-20 · GlobeNewswire
Oncolytics Biotech® Secures New U.S. Patent Protecting Commercial Manufacturing of Pelareorep into 2044
2026-06-16 · GlobeNewswire